



OxySure Therapeutics, Inc. (OXYS)

Corporate Presentation
February 2016

It's About Time.

Forward Looking Statements

The following may contain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this communication, including statements relating to our growth strategy, financial results, product approvals, and development programs, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance to differ materially from the forward-looking statements we make include: range of treatment options, clinical applications, and market acceptance of products and other risks detailed from time to time in our filings with the Securities and Exchange Commission. Our actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors.



Introduction

Oxygen from Powder

Dry, Inert, Safe: Oxygen on demand

Medical Device Company

Mass markets

- Business
- Consumer

Launch product

- OxySure Model 615
- FDA approved, OTC
- CE Marking approved

Ready Market

AED Companion Market

- US: 2 million unit installed base, growing 8% annually
- Worldwide: 3 million unit installed base, growing 10% annually



OxySure Model 615: It's About Time.™

Advantages

- Non-Compressed Source
- No Training required
- Safe
- No Prescription Required
- Lightweight
- Disposable Cartridge
- Easy Operation
- 6 liters per minute, 15-20 minutes
- 99% + Medical oxygen
- Rest is moisture



Benefits & Features

- Safety
- No maintenance required
- No hydrostatic testing required
- Can be shipped "rescue ready"
- No licenses or permits required
- Ideal AED companion

Pricing

- **Base unit: \$349**
- **Cartridge: \$149**



It's About Time.

We're Saving Lives!

4,000+, and counting!

1

PLUG IN THE MASK



2

TURN THE KNOB



3


PLACE THE MASK OVER
THE NOSE AND MOUTH



oxySure
OXYGEN FROM POWDER

It's About Time.

Recent Milestones



Recent Awards

2014 US Patent & Trademark Office (USPTO) selects OxySure for Innovation Expo at Smithsonian Museum

2015 Top 5 Award Recipient in Fastech – fastest growing Texas Companies with 802% growth

2010 Lone Star Award for Innovation in Respiratory Technology


2010 Featured news story on WFAA Channel 8

2009 Featured in Fortune Small Business and CNN.com

2010 IMPACT Awards

2008 Tech Titans Innovation Award

2008 World's Best Technologies



Where is OxySure needed?

- “Bridging the Gap”
- Gap = Emergency Onset → Arrival of First Responders
- USA Today: Gap is 6 - 15 Minutes
- AEDs Address This Gap



“OxySure enables a loved one, bystander or even the person himself to provide oxygen while awaiting the arrival of emergency medical responders.”



Dr. Vincent Mosesso,
University of Pittsburgh Medical Center
Founder, Sudden Cardiac Arrest
Association (SCAA)



Just like AEDs...

Automated External Defibrillator (AED):

- Average Price: \$1,500 (started in \$5,000 range)
- Batteries and pads replaced every 2 years (\$400)



Units sold and pre-positioned since 2001:

USA, approx. 2 Million units –
Growing approx. 8.8% p.a.

\$1.7 Billion in 2015, USA only

ROW, approx. 3 Million units –
Growing approx. 10% p.a.

**Rise in demand for AEDs from alternate care and public access segments fueled by Legislation:
(1) Cardiac Arrest Survival Act (CASA) (2) State Mandates; and Increasing awareness.*



Just like AEDs...

**Except... 300x more
likely to need
Oxysure vs. AED!**



Problems w/ Existing Emergency Oxygen

- **Compressed Cylinders**

- Explosion hazard
- Heavy
- Expensive to purchase and maintain

- **Chemical Generators**

- No widespread consumer application
- Produces high heat
- Explosion hazard
- Highly toxic

- **Costs**

- Range \$369 - \$899 (OxySure Model 615 - \$349)



Where is OxySure Needed?

“Placement” Markets

- 20,000,000 OSHA Compliant Buildings
- 116,000,000 Homes and Apartments
- 7,000+ MRI Centers
- POC Markets, Alternate Sites
- 100,000 K-12 Schools
- 6,000,000 Residential Swimming Pools
- 925,000 Restaurants
- 350,000 Manufacturing Facilities
- 325,000 Places of Worship
- 16,000 Golf Courses
- Airports, Public Use Facilities, Sports Facilities




Who Needs OxySure?

“At Risk” Markets

- Cardiovascular Disease
 - 40 Million Diagnosed
 - 40 Million Undiagnosed
- Chronic Obstructive Pulmonary Disease (COPD)
 - 16 Million Diagnosed
 - 14 Million Undiagnosed
 - 1.6 Million on Long Term Oxygen Therapy (Back-up)
- Asthma – 22.3 million
- General medical & civil emergencies
- Travelers to higher altitudes
- Private pilots – 400,000
- Over 50

How Do We Sell?



Marketing support:

Trade shows


National Safety Congress, ECCU (US)
Medica (Germany)
RETTMobil (Germany)
Hospitalar (Brazil)

Media


Industrial Hygiene News
Sports magazines
Education newsletters
Online



Where Are We Today in US?



Where Are We Today Outside US?



Manufacturing/Operations




GMP / ISO 13485
Scalable
100% Made in USA



It's About Time.

Product Diversification



Purchase Order

Date November 10, 2015

Ed Huntsberry - ehuntsberry@oxysure.com

Bill To:

Name

Company Dolese

Acct. # (if applicable)

Address 20 NW 13th Street

City Oklahoma City State OK Zip 73103

Phone 405-297-8228

Fax

E-mail @dolese.com

Ship To:

Name

Company







Address

City State Zip

PO#

Phone

E-mail

Qty	Part #	Description		Totals
10	615-00 / 615-09	Rescue ready OxySure Model 615, Emergency Oxygen System. includes adult mask and thermal jump bag, for mobility and protection. 	\$438.00	\$4,380.00
10	9390A-1001P	Cardiac Science Powerheart G3 Plus Automatic AED. Includes carrying case, 4 year battery, 2 set of adult pads, ready kit, 7 year warranty and owners manual. 	\$1,349.00	\$13,490.00
10	615-15	OxySure combination AED/OxySure surface mounted double wall box with alarm. When seconds count, using a single easy access point for both devices, in an emergency, reducing response time and risk. 	\$369.00	\$3,690.00
10	615-AED	Projecting "V" shape AED sign. Emergency signs visible from all sides. 	\$18.00	\$180.00
10	615-07	Projecting "V" shape Oxygen sign. Emergency signs visible from all sides. 	\$18.00	\$180.00
10	615-12	OxySure standard pulse Oximeter to monitor blood oxygen levels and heart rate. 	\$99.00	\$990.00

****Credit Card Purchase-Card on file**

SUB-TOTAL \$22,910.00
TAX (TX=8.25%)
SHIPPING \$169.00
TOTAL: **\$23,079.00**

Shipping Options:

Carrier (select only one):
☐ OxySure Carrier
☐ Other:

Shipment Type (select only one):
☐ Next Day
☐ Second Day
☐ Ground

x Shipping Terms: FOB Frisco, Texas

Credit Card Info:

Type of Card: MC VISA AMEX DISC

Card #:

Exp Date:

CVV Code:

Card Name:

Zip Code:



Northwest Independent School District

P.O. Box 77070 Fort Worth, TX 76177-0070
Phone (817) 215-0047 FAX (817) 215-0009

PURCHASE ORDER

PAGE: 1

PURCHASE ORDER NO.

633

IMPORTANT: Purchase order number must appear on all invoices, packages, and other correspondence.

VENDOR: 115285 FAX: 972-294-6501
OXYSURE SYSTEMS, INC
10880 JOHN W ELLIOTT DRIVE
SUITE #600
FRISCO TX 75033

E-MAIL INVOICES TO:
OR SEND INVOICES IN DUPLICATE TO:
Northwest ISD
Attn: Accounts Payable
P.O. Box 77070
Fort Worth, TX 76177-0070

SH NORTHWEST IND SCHOOL DISTRICT
1800 HWY 114
JUSTIN, TX 76247
ATTN: [REDACTED] 9

TERMS: NET 30 DAYS		F.O.B		DESC: EPCNT/FISD	DELIVERY: Feb. 21, 2015	
ITEM	ITEM NO.	QUANTITY	U.O.M.	DESCRIPTION	UNIT PRICE	EXTENSION
01	615-00	5		MODEL 615 EMERGENCY OXYGEN SYSTEM	329.0000	1,645.00
02	615-01	25		MODEL 615 REPLACEMENT CARTRIDGE	129.0000	3,225.00
03		1		BOTH ITEMS INCLUDE MASK WITH TRAY ASSEMBLY.	.0000	.00
04	615-04	4		REPLACEMENT MASKS, CHILD	27.5000	110.00
05	615-05	1		SURFACE MOUNTED WALL BOX	349.0000	349.00
06	615-07	7		OXYGEN SIGNS	18.9500	132.65

TAX EXEMPTION # 1-75-6003004-5.
Northwest ISD is exempt from payment of sales, excise, or use taxes under Chapter 20, Title 122A, Revised Civil Statutes of Texas (Articles 20.04 (F) (4)).

APPROVED BY:

FINANCIAL OFFICER

PAGE TOTAL \$ 5,461.65
TOTAL \$ 5,461.65

ADJSE. REC'D BY: _____
DATE: _____
REQUISITION NO. [REDACTED]

ITEM #	ACCOUNT	AMOUNT	PROJECT CODE
01	1995339999 [REDACTED] 9900	1,645.00	
02	1995339999 [REDACTED] 9900	3,225.00	
03	1995339999 [REDACTED] 9900	.00	
04	1995339999 [REDACTED] 9900	110.00	
05	1995339999 [REDACTED] 9900	349.00	
06	1995339999 [REDACTED] 9900	132.65	



Future product development



Emergency Drone
(for Military and First response – Carry Medical Payloads)



OxyPak
**Military Special Forces / Commercial First Responders – Handheld
oxygen device for Combat Use**



Self-Contained, Self-Rescuer Solution
Mining / Navy markets (30 M + units)



Consumable Flex-Pak
Sports & Recreation (100 M + units)



Automobile market
“Drop down” for deployment in any accident



Wound care / Skin care markets



Revenue trends by Quarter

	3Q12	4Q12	1Q13	2Q13	3Q13	4Q13	1Q14	2Q14	3Q14	4Q14	1Q15	2Q15	3Q15
Revenues	103,327	75,595	240,420	476,071	545,819	538,017	356,228	678,112	818,456	584,606	624,514	1,045,693	1,138,380
Growth%	380%	16%	747%	655%	428%	612%	48%	42%	50%	9%	75%	54%	39%

Annual revenues

	FY2012	FY2013	FY2014
Revenues	269,697	1,800,327	2,437,402
Revenue Growth	84,488	1,530,630	637,075
Growth%	46%	568%	35%

Average *quarterly* growth rate: **243%**

Average *annual* growth rate: **216%**



3Q 2015 Financial Highlights

- Total revenue up 39% to \$1,138,380 (three months)
- Total revenue up 52% to \$2,809,553 (nine months)
- Gross profit up 12% to \$558,254 (three months)
- Gross profit up 40% to \$1,484,388 (nine months)
- Total cash up 210% to \$2,006,312 from \$647,093
- Working capital surplus up 253% to \$1,479,075 from \$418,734
- Total assets up 76% to \$4,424,003 from \$2,511,448
- Stockholder equity up 103% to \$2,180,918 from \$1,074,788
- Net loss \$.04 per share




Other Key Highlights

- 14th Consecutive growth quarter
- TTM revenue \$3.4 million
- Revenue run rate approaching \$5 million
- **On track for revenue run rate of \$10 million in 2016**
- Adjusted EBITDA in 3Q15 was \$(76,000), -6.7%
- **On track for breakeven in 2016**
 - Cash flow breakeven first
 - GAAP breakeven later




3Q 2015 Financial Results

3-Month Results – 3Q15 v 3Q14 (in thousands)




3Q 2015 Financial Results

9-Month Results – 3Q15 v 3Q14 (in thousands)



3Q 2015 Financial Results

Balance Sheet Items – 9/30/15 v 12/31/2014 (in thousands)



Other Financial Items

- Capital leases retired
- \$2 Million in capital equipment off balance sheet
- Deferred income tax assets of \$5.6 million
- Other balance sheet items

Other Highlights

- Supply agreement with ORS Nasco
- Advisory Board: Dr. Zachariah, Dr. Chalil, Chris Kaplan
- Teamed up with MedOne for customer leasing of equipment
- Expanded manufacturing capacity to address backlog
- Completed name change




Other Highlights, cont.

- Operational efficiencies
- Expanded sales staff
- Received Commercial Drone Approval from FAA
- Placed 4th on Fastest Growing Companies with 804% growth



Medical Device Platform Vision



OxySure Circle of Success

Insurance
Legislation
Regulatory
Legal



Growth Strategy Next 3-5 Years

Grow Placement Markets

- Grow distributors; US + ROW
- Grow strategic accounts teams
- Pursue legislation / mandates
- Aggressively pursue 3 million+ unit 'AED companion' market, and 100 million+ unit general placement markets
- Services

Grow At Risk Markets

- Pursue insurance reimbursement (Medicare, private)
- Execute rolling short/long form commercial campaign(s) targeting 100 million+ US and 500 million+ ROW 'at risk' customers
- Services

New Vertical Mass Markets

- Military
- Mining
- Aviation
- Sports/Recreation
- Skin care
- Wound care
- Automotive

+ Strategic Alliances



OxySure Leadership

- **Julian T. Ross, MBA – Chairman & CEO**

- ✓ OxySure founder and CEO since inception
- ✓ 27+ years experience in technology, manufacturing, and finance; holds 7 patents
- ✓ Managed development of our production capabilities, partnerships and alliances, managed the development of sales, distribution and licensing partnerships, raised in excess of \$24 million in debt and equity to fund operations, and took OXYS public in 2011 through an S-1 registration with the Securities and Exchange Commission.
- ✓ Other experience: Roll-up, technology companies; \$315 million high yield debt offering (Merrill Lynch/Salomon Brothers in lead, plus Deutsche Morgan Grenfell, Nomura Securities)

- **Jeremy “Jerry” Jones, Director**

- ✓ 35+ Years in healthcare leadership
- ✓ Former Chairman/CEO of Apria Healthcare (sold to Blackstone for \$1.7 billion)
- ✓ Chairman of On Assignment (NYSE: ASGN), \$1.6 billion healthcare services leader

- **Thomas Cox, B.Acc., Director**

- ✓ Advisor to PE firms KKR; Harvest Partners
- ✓ Former EVP Sales to MSC Industrial; grew sales from \$500 million to \$3 Billion with 3,000 employees
- ✓ 30+ Years in Sales Management, Corporate Development, and Mergers & Acquisitions

- **Clark Hood, BBA, VP Resuscitation Sales Worldwide**

- ✓ 25+ years experience in sales and sales management, in healthcare, medical devices and emergency medical equipment.
- ✓ VP of Resuscitation Cardiac Science (16 years), a global medical device manufacturer of automated external defibrillation (AED) products and management services in over 100 countries.



Strategic Advisory Board

- **Dr. Zach Zachariah, MD**

- ✓ Cardiologist; Florida Board of Medicine; President, American Heart Association
- ✓ National Heart, Lung and Blood Advisory Council (NIH); Former Director of Ivax (acquired by Teva Pharmaceutical (NYSE: TEVA) for \$7.4 billion

- **Dr. Vincent Mosesso, Jr., MD, FACEP**

- ✓ Founder / Medical Director of Sudden Cardiac Arrest Association (SCAA)
- ✓ Medical Director for Pre-hospital Care at the University of Pittsburgh Medical Center (UPMC)

- **Dr. Joseph M. Chalil, MD, MBA, FACHE**

- ✓ Boehringer Ingelheim Physician Executive; Expert in US Healthcare policy
- ✓ Chairman of Global Clinical Research and Trial Network; Published in American Journal of Respiratory and Critical Care Medicine

- **Dr. James R. Winn, MD**

- ✓ 38 Years' experience in the healthcare industry, both as a policy maker and as a physician in practice
- ✓ Former Chief Executive Officer of the Federation of State Medical Boards (FSMB) of the United States

- **Dr. Thomas D. Franklin, Jr.**

- ✓ 40 Years' experience in medical research, education and leadership
- ✓ Sr. Scientific Advisor to Ntec; Former President of the Texas Health Research Institute

- **Dr. Jonathan E. Burke, DMD**

- ✓ Significant experience in hyperbaric oxygen therapy and received an Attending Hyperbaric Medicine Certificate in 1996
- ✓ Oral and maxillofacial surgeon for the Philadelphia Flyers and Phantoms professional hockey clubs since 1994



Summary

- Rapid growth mode (Growing Sales, Sales Force, Distribution)
- Expect \$10 million run rate, breakeven in 2016
- Great market position
 - Intellectual property
 - First mover advantage
 - “No brainer” strategy to piggy back off of AED growth
 - Large growing and natural markets
- Future products, verticals and markets
- Medical device platform company



Contact Information

OxySure Therapeutics, Inc.

OXYS: OTCQB

10880 John W. Elliott Road, Suite 600

Frisco, TX 75034 USA

Tel: (+1) 972-294-6450

info@oxysure.com

www.OxySure.com



Redchip Companies, Inc.

800-733-2447, ext. 107

Jon Cunningham

jon@redchip.com

www.redchip.com/

